5-Year Experience With Transcatheter Transapical Mitral Valve-in-Valve Implantation for Bioprosthetic Valve Dysfunction
Why the study?
With increasing implantation of mitral bioprostheses, transcatheter valve-in-valve implantation may offer a lower-risk alternative for high-risk patients experiencing mitral valve degeneration.
Is transapical mitral transcatheter valve-in-valve implantation safe and effective for high-risk patients with severe mitral bioprosthetic valve dysfunction?
Comparison
Transapical mitral transcatheter valve-in-valve implantation
Design
Consecutive case series
Follow-up
Median 753 days
Authors
Discussion
Loading...
Member takes
Implication
Hypothesis-generating for transapical mitral TVIV in high-risk bioprosthetic failure; leaves open randomized trials before clinical adoption.
Structured PICO
Is transapical mitral transcatheter valve-in-valve implantation safe and effective for high-risk patients with severe mitral bioprosthetic valve dysfunction?
P
Population
23 consecutive elderly patients (mean age 81 ± 6 years) with severe mitral bioprosthetic valve dysfunction (stenosis, regurgitation, or combined) at high-risk for conventional redo surgery (STS score 12.1 ± 6.8%).
I
Intervention
Transapical mitral transcatheter valve-in-valve implantation (TVIV) using balloon expandable valves.
O
Outcome
Procedural success, intraoperative complications, hemodynamics, and survival at 30 days and midterm follow-up.hard clinical
Transapical mitral valve-in-valve implantation is a feasible and safe alternative for high-risk patients with degenerated mitral bioprostheses, offering excellent midterm survival and hemodynamic outcomes.
Cite This Study
Cheung et al. (2013) studied this question.